Episode 104 — Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards

The new FDA Commissioner’s National Priority Voucher (CNPV) pilot program promises to reduce recipients’ application review times from 10-12 months to just 1-2 months.  As part of the Trump administration’s push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA’s entry into the drug pricing fray.  In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns.

Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.

Read our bi-weekly Drug Pricing Digest or subscribe to receive future editions in your inbox.